[{"id":"4b6f2c6e-35f3-4b56-9b34-2f31c986974d","acronym":"BNT111-01","url":"https://clinicaltrials.gov/study/NCT04526899","created_at":"2021-01-18T21:40:45.863Z","updated_at":"2025-02-25T15:26:32.109Z","phase":"Phase 2","brief_title":"Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma","source_id_and_acronym":"NCT04526899 - BNT111-01","lead_sponsor":"BioNTech SE","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • BNT111"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-10"},{"id":"89a914ac-06d5-4cf1-bba9-6ccd8e3df332","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083883","created_at":"2023-10-16T16:13:47.307Z","updated_at":"2024-07-02T16:34:59.004Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","source_id_and_acronym":"NCT06083883","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B • SSX1","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2024-06-04"},{"id":"8af52e0c-a6ec-4403-a6fa-b9543bc969cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066359","created_at":"2023-10-04T15:10:43.929Z","updated_at":"2024-07-02T16:34:59.118Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06066359","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-06-04"},{"id":"1da77410-a879-4bd0-ac76-26adfb53609a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05989828","created_at":"2023-08-14T14:10:18.266Z","updated_at":"2024-07-02T16:35:01.088Z","phase":"Phase 1","brief_title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","source_id_and_acronym":"NCT05989828","lead_sponsor":"University of Southern California","biomarkers":" HER-2 • PD-L1 • ER • PGR • CTAG1B","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-24"},{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"aa19e127-4a6d-4543-94a8-fa9ef6096cb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881525","created_at":"2023-05-31T15:05:39.768Z","updated_at":"2024-07-02T16:35:09.880Z","phase":"Phase 1","brief_title":"NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05881525","lead_sponsor":"TCRCure Biopharma Ltd.","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-12"},{"id":"211eeb3f-139e-420f-ae87-06572b73ee2a","acronym":"PRECIOUS-01","url":"https://clinicaltrials.gov/study/NCT04751786","created_at":"2021-02-12T13:55:47.252Z","updated_at":"2024-07-02T16:35:10.395Z","phase":"Phase 1","brief_title":"Dose Escalation Study of Immunomodulatory Nanoparticles","source_id_and_acronym":"NCT04751786 - PRECIOUS-01","lead_sponsor":"Radboud University Medical Center","biomarkers":" CD20 • CD8 • CTAG1B • FOXP3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD8 • CTAG1B • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PORT-3"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-10"},{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"aafc6a72-033b-4470-9c1d-5d77ddce9a83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05549921","created_at":"2022-09-22T15:56:31.418Z","updated_at":"2024-07-02T16:35:25.127Z","phase":"Phase 2","brief_title":"Phase II Study of TAEST16001 in Soft Tissue Sarcoma","source_id_and_acronym":"NCT05549921","lead_sponsor":"Sun Yat-sen University","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAEST16001"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-27"},{"id":"96478ee8-ea1d-46f0-9076-86b0a0a5b146","acronym":"","url":"https://clinicaltrials.gov/study/NCT02869217","created_at":"2021-02-16T02:53:03.033Z","updated_at":"2024-07-02T16:35:26.728Z","phase":"Phase 1","brief_title":"Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors","source_id_and_acronym":"NCT02869217","lead_sponsor":"University Health Network, Toronto","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-08"},{"id":"2af4501d-3698-4fa1-bef4-a73d1a7b2ae3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250325","created_at":"2021-02-16T02:53:12.531Z","updated_at":"2024-07-02T16:35:26.928Z","phase":"Phase 1/2","brief_title":"Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma","source_id_and_acronym":"NCT03250325","lead_sponsor":"Takara Bio Inc.","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 03/09/2022","study_completion_date":" 03/09/2022","last_update_posted":"2023-12-06"},{"id":"d41013a9-659b-4bd4-843d-44f12482f427","acronym":"STELLA","url":"https://clinicaltrials.gov/study/NCT02475707","created_at":"2021-01-18T11:55:12.467Z","updated_at":"2024-07-02T16:35:31.622Z","phase":"Phase 1","brief_title":"Administration of Donor MultiTAA-Specific T Cells for ALL","source_id_and_acronym":"NCT02475707 - STELLA","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD8 • CD4 • MME","pipe":"","alterations":" ","tags":["CD8 • CD4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/29/2019","primary_completion_date":" 10/29/2019","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-26"},{"id":"4c345493-ab62-410a-b773-a42c655f0249","acronym":"PDC-LUNG-101","url":"https://clinicaltrials.gov/study/NCT03970746","created_at":"2021-01-18T19:31:48.798Z","updated_at":"2024-07-02T16:35:31.964Z","phase":"Phase 1/2","brief_title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","source_id_and_acronym":"NCT03970746 - PDC-LUNG-101","lead_sponsor":"PDC*line Pharma SAS","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed • PDC*lung"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 09/10/2019","start_date":" 09/10/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-24"},{"id":"02699193-e287-431a-b255-1adc890318f2","acronym":"NCI-2018-00926","url":"https://clinicaltrials.gov/study/NCT03450122","created_at":"2021-01-19T15:37:56.641Z","updated_at":"2024-07-02T16:35:33.518Z","phase":"Phase 1","brief_title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","source_id_and_acronym":"NCT03450122 - NCI-2018-00926","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-10-16"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"0648059d-a94a-4543-9c17-30dd3ccc0c5a","acronym":"Lipo-MERIT","url":"https://clinicaltrials.gov/study/NCT02410733","created_at":"2021-01-18T11:30:56.690Z","updated_at":"2025-02-25T16:24:31.238Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma","source_id_and_acronym":"NCT02410733 - Lipo-MERIT","lead_sponsor":"BioNTech SE","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT111"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 06/20/2023","study_completion_date":" 06/20/2023","last_update_posted":"2023-07-19"},{"id":"9eac4268-8e45-4c25-be18-2972151ca188","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494167","created_at":"2021-01-18T12:01:22.240Z","updated_at":"2024-07-02T16:35:45.346Z","phase":"Phase 1","brief_title":"Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)","source_id_and_acronym":"NCT02494167","lead_sponsor":"Baylor College of Medicine","biomarkers":" KIT • WT1 • CD33 • ANPEP","pipe":"","alterations":" ","tags":["KIT • WT1 • CD33 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-06-19"},{"id":"9f1bb930-90b6-47c8-bc95-d55cb1f1fabb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318964","created_at":"2021-01-19T19:31:04.586Z","updated_at":"2024-07-02T16:35:50.876Z","phase":"Phase 1","brief_title":"TAEST16001 in the Treatment of Soft Tissue Sarcoma","source_id_and_acronym":"NCT04318964","lead_sponsor":"Sun Yat-sen University","biomarkers":" IL6 • CTAG1B","pipe":"","alterations":" ","tags":["IL6 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAEST16001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 04/15/2022","primary_completion_date":" 04/15/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-04-12"},{"id":"d924c9a5-111c-4192-ac55-a94b62900700","acronym":"","url":"https://clinicaltrials.gov/study/NCT03462316","created_at":"2021-01-19T15:41:01.893Z","updated_at":"2024-07-02T16:35:50.717Z","phase":"Phase 1","brief_title":"NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma","source_id_and_acronym":"NCT03462316","lead_sponsor":"Sun Yat-sen University","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TAEST16001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 02/15/2024","primary_completion_date":" 02/15/2024","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2023-04-12"},{"id":"bdb8eace-af07-466b-a0e7-cc3562eb74f5","acronym":"ADP-0011-007","url":"https://clinicaltrials.gov/study/NCT02992743","created_at":"2021-02-16T02:53:04.030Z","updated_at":"2024-07-02T16:35:50.904Z","phase":"Phase 2","brief_title":"Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma","source_id_and_acronym":"NCT02992743 - ADP-0011-007","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-04-11"},{"id":"1cfc9dae-087d-4a45-888a-feae0e1a43ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02166905","created_at":"2021-01-18T10:05:33.255Z","updated_at":"2024-07-02T16:35:54.811Z","phase":"Phase 1/2","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","source_id_and_acronym":"NCT02166905","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2023-02-24"},{"id":"4b902844-e9bb-481c-9882-6b4cdce12c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT04878484","created_at":"2021-05-07T11:53:02.821Z","updated_at":"2024-07-02T16:36:04.497Z","phase":"Phase 1","brief_title":"Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04878484","lead_sponsor":"Athenex, Inc.","biomarkers":" CD8 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CTAG1B expression","tags":["CD8 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TCRT-ESO-A2"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-02"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"},{"id":"6e060b6a-aecb-4f0c-b730-57d52b351ad4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358719","created_at":"2021-01-19T15:11:58.492Z","updated_at":"2024-07-02T16:36:23.457Z","phase":"Phase 1","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT03358719","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • decitabine • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 03/27/2018","start_date":" 03/27/2018","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 08/25/2021","study_completion_date":" 08/25/2021","last_update_posted":"2021-10-05"}]